An Open-label Study of AZD0120 in Adults With Multiple Sclerosis
← catalyst calendarNCT07224373 · readout in 846 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
24estimated
Sites
19
Countries
Australia, Canada, Germany +2
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-12-09 | actual | When the study began enrolling |
| Primary completion | 2028-12-12 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-12-12 | estimated | The whole study's end, after follow-up |
| First posted | 2025-11-04 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-27 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Multiple Sclerosis
Interventions
- Biological: AZD0120 - Regimen 1
- Biological: AZD0120 - Regimen 2
Primary outcomes
what the primary-completion date above is the date OFEvaluate the safety, and tolerability of AZD0120 in participants with MS (disease cohort 1: RMS; disease cohort 2: PMS)
measured Day 1 to day 29, and over 104 weeks
Evaluate the safety, and tolerability of AZD0120 in participants with MS (disease cohort 1: RMS; disease cohort 2: PMS)
measured Day 1 to day 29, and over 104 weeks
Evaluate the safety, and tolerability of AZD0120 in participants with MS (disease cohort 1: RMS; disease cohort 2: PMS)
measured Day 1 to day 29, and over 104 weeks
Evaluate the safety, and tolerability of AZD0120 in participants with MS (disease cohort 1: RMS; disease cohort 2: PMS)
measured Day 1 to day 29, and over 104 weeks
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed